# CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))

> **NCT04756141** · NA · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 20 (actual)

## Conditions studied

- Diabetes Mellitus
- Covid19

## Interventions

- **DEVICE:** Continuous Glucose Monitor (CGM)

## Key facts

- **NCT ID:** NCT04756141
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-03
- **Primary completion:** 2022-08-24
- **Final completion:** 2022-08-24
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04756141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04756141, "CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04756141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*